Development of vaccines for SARS-CoV-2.
COVID-19
SARS-CoV-2
Vaccines
Journal
F1000Research
ISSN: 2046-1402
Titre abrégé: F1000Res
Pays: England
ID NLM: 101594320
Informations de publication
Date de publication:
2020
2020
Historique:
accepted:
07
08
2020
entrez:
28
8
2020
pubmed:
28
8
2020
medline:
2
9
2020
Statut:
epublish
Résumé
COVID-19 emerged in late 2019 and has rapidly spread through many countries globally. The causative SARS-CoV-2 virus was not known until recently, and there is little or no natural immunity in human populations. There is an urgent need for vaccines and drugs to combat this new pandemic. In just a few months, huge efforts and resources by government, academia, and industry have been thrown into the race to develop a vaccine. This brief review summarizes and discusses the array of technologies being applied to vaccine development, highlighting the strengths and weaknesses of the various approaches.
Identifiants
pubmed: 32850116
doi: 10.12688/f1000research.25998.1
pmc: PMC7431966
pii:
doi:
Substances chimiques
COVID-19 Vaccines
0
Spike Glycoprotein, Coronavirus
0
Viral Vaccines
0
spike protein, SARS-CoV-2
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright: © 2020 Ng WH et al.
Déclaration de conflit d'intérêts
No competing interests were disclosed.No competing interests were disclosed.No competing interests were disclosed.
Références
Proc Natl Acad Sci U S A. 2012 Sep 4;109(36):14604-9
pubmed: 22908294
N Engl J Med. 2020 Jul 14;:
pubmed: 32663912
Immunology. 2004 Oct;113(2):163-74
pubmed: 15379976
Lancet. 2004 Dec 18-31;364(9452):2181-7
pubmed: 15610804
Front Immunol. 2019 Jun 04;10:1250
pubmed: 31231383
MMWR Morb Mortal Wkly Rep. 2016 Sep 09;65(35):934-8
pubmed: 27606675
Expert Rev Vaccines. 2012 Jun;11(6):695-719
pubmed: 22873127
Nat Rev Drug Discov. 2020 May;19(5):305-306
pubmed: 32273591
Biotechnol Bioeng. 2012 Jun;109(6):1443-60
pubmed: 22407777
Nat Biotechnol. 2020 Jan;38(1):6
pubmed: 31919440
Nature. 2017 Mar 9;543(7644):248-251
pubmed: 28151488
Mol Ther. 2017 Jun 7;25(6):1316-1327
pubmed: 28457665
Clin Exp Vaccine Res. 2012 Jul;1(1):35-49
pubmed: 23596576
Sci Rep. 2018 Jan 18;8(1):1125
pubmed: 29348555
Rev Prat. 1995 Jun 15;45(12):1488-91
pubmed: 7660001
J Virol. 2020 Feb 14;94(5):
pubmed: 31826992
Front Immunol. 2018 Apr 23;9:597
pubmed: 29740424
Adv Drug Deliv Rev. 2015 Oct 1;93:56-78
pubmed: 25312673
Expert Rev Vaccines. 2009 May;8(5):607-18
pubmed: 19397417
Nature. 2020 Jul 30;:
pubmed: 32731258
J Virol. 2019 Aug 13;93(17):
pubmed: 31189716
Vaccine. 2020 Mar 23;38(14):2943-2948
pubmed: 32107060
Int J Mol Sci. 2018 Nov 15;19(11):
pubmed: 30445702
Lancet. 2020 Jun 13;395(10240):1845-1854
pubmed: 32450106
Nature. 2020 Apr;580(7805):576-577
pubmed: 32346146
Vaccines (Basel). 2016 Apr 19;4(2):
pubmed: 27104575
Elife. 2014 Dec 09;3:e04531
pubmed: 25490153
Vaccines (Basel). 2013 Jun 25;1(3):225-49
pubmed: 26344110
J Virol. 2014 Sep;88(18):10525-40
pubmed: 24965472
Nat Rev Immunol. 2020 Jun;20(6):339-341
pubmed: 32317716
Int J Infect Dis. 2020 Feb;91:264-266
pubmed: 31953166
Vaccines (Basel). 2014 Jul 29;2(3):624-41
pubmed: 26344749
Front Immunol. 2019 Mar 27;10:594
pubmed: 30972078